Education
About Us
Working with TipRanks
Follow Us
CV Sciences Inc (CVSI)
OTHER OTC:CVSI
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
>-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 09, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong efforts in maintaining a healthy gross margin, progress in market share and product innovation, and advancements in M&A strategies. However, these positives were tempered by a decline in revenues, manufacturing challenges, and regulatory impacts. Despite the revenue decline, the company's strategic initiatives and improved cost efficiencies present an optimistic outlook.Company Guidance
During the first quarter of 2025, CV Sciences reported a revenue of $3.6 million, a slight decline from $3.9 million in the fourth quarter of 2024, with a gross margin of 46%. The company achieved an EBITDA of $131,000 and an adjusted EBITDA loss of $311,000, while managing to decrease SG&A expenses to $2.1 million, reflecting a 12% year-over-year reduction. Despite lower unit sales due to state regulations and supply chain disruptions, new products launched since early 2023 contributed to 35% of the quarter's revenue. The company also improved its net loss to $0.1 million, compared to $0.7 million in the previous quarter, and increased its cash position to $0.8 million by securing a $1.2 million financing agreement. Strategic initiatives, including the acquisition of Elevated Softgels and Cultured Foods, are expected to enhance cost efficiency and profitability, with positive cash flow anticipated in the latter half of 2025.Healthy Gross Margin Maintained
CV Sciences maintained a gross margin of 46% in Q1 2025, demonstrating continued efficiency and cost management.
Market Share and Product Innovation
The company maintained its number one position in the natural product retail channel and increased market share. It also launched new product lines, including non-cannabinoid products under the Lunar Fox brand and new product formats like effervescent tablets.
M&A Strategy Progress
Integration of the Elevated Softgels acquisition is expected to improve cost efficiency and gross margins in the second half of 2025 through in-sourcing manufacturing.
Positive EBITDA
Achieved EBITDA of $131,000, with adjustments leading to an adjusted EBITDA loss of $311,000, indicating improved financial performance.
Improved Operating Cash Flow
The company improved its cash usage from operations to $0.1 million in Q1 2025 compared to $0.2 million in Q4 2024, moving closer to positive operating cash flow.
CVSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CVSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 09, 2025 | $0.03 | $0.03 | 0.00% |
Mar 27, 2025 | $0.03 | $0.03 | 0.00% |
Nov 14, 2024 | $0.04 | $0.04 | 0.00% |
Aug 13, 2024 | $0.06 | $0.05 | -16.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CV Sciences Inc (CVSI) report earnings?
CV Sciences Inc (CVSI) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is CV Sciences Inc (CVSI) earnings time?
CV Sciences Inc (CVSI) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CVSI EPS forecast?
Currently, no data Available